The New York Entrepreneur

Amgen’s obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to come

Read Time:6 Second

One analyst says Amgen’s stock is in the ”early innings of a large move,” fueled by an experimental obesity drug.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post ISM service-sector gauge weakens sharply in April
Next post Goldman Sachs settles lawsuit that alleged violations in platinum and palladium trading